Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 438-446, 2007. First published January 26, 2007; 10.1373/clinchem.2006.076158
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 076158.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.076158v1
53/3/438    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Børglum, T.
Right arrow Articles by Hilsted, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Børglum, T.
Right arrow Articles by Hilsted, L.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2007;53:438-446.)
© 2007 American Association for Clinical Chemistry, Inc.

Cancer Diagnostics

Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas

Tine Børglum1, Jens F. Rehfeld1, Lars B. Drivsholm2 and Linda Hilsted1,a

1 University Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
2 Department of Oncology, Storstrømmens Sygehus Næstved, Denmark.

aAddress correspondence to this author at: Department of Clinical Biochemistry KB, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen Ø, Denmark. Fax 45-35-45-46-40; e-mail linda.hilsted{at}rh.hosp.dk.

Background: Most neuroendocrine tumors express chromogranin A (CgA). The posttranslational processing of neuroendocrine proteins such as CgA is often specific for the individual tumor. To cope with this variability and improve tumor diagnosis, we developed a processing-independent analysis (PIA) method to measure the total CgA product.

Methods: For PIA, samples underwent trypsin treatment followed by measurement of CgA by the "CgA(340->)" assay, in which the antiserum binds an epitope starting at amino acid 340 of CgA and including amino acid residues located in the C-terminal direction. The diagnostic accuracy of the CgA PIA and 3 sequence-specific assays for CgA were evaluated on plasma samples from patients with neuroendocrine tumors and small-cell lung carcinomas. Furthermore, we investigated whether the CgA plasma concentrations correlated with the tumor burden.

Results: Size-exclusion chromatography of plasma showed that CgA immunoreactivity mainly consisted of high–molecular-weight forms, indicating that neuroendocrine tumors may secrete large amounts of poorly processed CgA. Accordingly, trypsination of plasma from 54 patients with neuroendocrine tumors or small-cell lung carcinomas increased the CgA(340->) immunoreactivity up to 500-fold. Both the CgA(340->) assay and the PIA measured significantly higher plasma concentrations in patients with very extensive disease than in patients with less widespread disease. The diagnostic sensitivity was 0.91 when using the CgA(340->) assay and 0.82 using the CgA PIA.

Conclusion: The CgA(340->) assay and CgA PIA are both useful for diagnosis of neuroendocrine tumors and small-cell lung carcinomas and both assays correlate with tumor burden.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cardiovasc ResHome page
K. B. Helle
The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions
Cardiovasc Res, August 18, 2009; (2009) cvp266v2.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.